Siamab Therapeutics is a biopharmaceutical company developing therapies targeting cancers that express abnormal carbohydrates/glycans. These highly cancer specific, tumor associated carbohydrate antigens (TACAs) are present in the majority of solid tumors including ovarian, pancreatic, prostate, colon, gastric, and breast, and are exploited by tumor cells to suppress innate immune function, enable tissue invasion and metastasis, resist chemotherapy, and promote a stem-cell phenotype. Therefore, therapeutic antibodies targeting TACAs have the potential to not only kill cancer cells but also re-engage the immune system and overcome chemo-resistance.
Siamab has developed a technology platform that enables the discovery of large numbers of highly specific, high affinity anti-TACA therapeutic antibodies. Siamab has brought together a world-leading team of scientists and advisors in oncology, glycoimmunology, and antibody engineering to support our anti-TACA antibody discovery and development programs.